The ubiquitin–proteasome pathway has been identified as a potential molecular target for
cancer therapy. In this study, we investigated the effect of the proteasome inhibitor …

Abstract Background and Objectives Targeting the ubiquitin–proteasome system by using
proteasome inhibitors represents a novel approach for cancer therapy. Anaplastic thyroid …

Context: The ubiquitin-proteasome pathway is a major pathway for degradation of
intracellular proteins. Proteasome inhibitors constitute a novel class of antitumor agents with …

Background The proteasome inhibitor bortezomib has shown impressive clinical activity
alone and in combination with conventional and other novel agents for the treatment of …

Conventional treatment by surgery, radioiodine, and thyroxin-suppressive therapy often fails
to cure anaplastic thyroid cancer (ATC). Therefore several attempts have been made to …

Proteasome inhibitors are promising antitumor drugs with preferable cytotoxicity in
malignant cells and have exhibited clinical efficiency in several hematologic malignancies …

Anaplastic thyroid cancer (ATC) is a rare thyroid malignancy representing 2% of thyroid
tumors. Usually, ATC is a lethal tumor with an overall median survival time\6 months from the …

Context: Our previous data showed that reactive oxygen species generation might be
ascribed to the cytotoxic response of thyroid cancer cells to proteasome inhibition and the …

Anaplastic thyroid cancer (ATC) is one of the most aggressive human malignancies, with no
effective treatment currently available. Previously, we identified agents active against ATC …

Introduction Medullary thyroid cancer (MTC) is a rare thyroid tumour whose management in
advanced stages is challenging, despite effective therapeutic options having expanded in …